
## Stella Manta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5633545/publications.pdf Version: 2024-02-01



**Stella Μανιτά** 

#	Article	IF	CITATIONS
1	Serotonin4 (5-HT4) Receptor Agonists Are Putative Antidepressants with a Rapid Onset of Action. Neuron, 2007, 55, 712-725.	3.8	294
2	Electrophysiological and neurochemical effects of long-term vagus nerve stimulation on the rat monoaminergic systems. International Journal of Neuropsychopharmacology, 2013, 16, 459-470.	1.0	136
3	Enhancement of the function of rat serotonin and norepinephrine neurons by sustained vagus nerve stimulation. Journal of Psychiatry and Neuroscience, 2009, 34, 272-80.	1.4	117
4	Polyunsaturated Fatty Acids Are Cerebral Vasodilators via the TREK-1 Potassium Channel. Circulation Research, 2007, 101, 176-184.	2.0	112
5	Optimization of vagus nerve stimulation parameters using the firing activity of serotonin neurons in the rat dorsal raphe. European Neuropsychopharmacology, 2009, 19, 250-255.	0.3	38
6	Stimulation of 5-HT2C Receptors Improves Cognitive Deficits Induced by Human Tryptophan Hydroxylase 2 Loss of Function Mutation. Neuropsychopharmacology, 2014, 39, 1125-1134.	2.8	32
7	Repetitive transcranial magnetic stimulation induces long-lasting changes in protein expression and histone acetylation. Scientific Reports, 2015, 5, 16873.	1.6	29
8	Dissociations between cognitive and motor effects of psychostimulants and atomoxetine in hyperactive DAT-KO mice. Psychopharmacology, 2014, 231, 109-122.	1.5	22
9	Novel attempts to optimize vagus nerve stimulation parameters on serotonin neuronal firing activity in the rat brain. Brain Stimulation, 2012, 5, 422-429.	0.7	20
10	Restoration of Serotonin Neuronal Firing Following Long-Term Administration of Bupropion but Not Paroxetine in Olfactory Bulbectomized Rats. International Journal of Neuropsychopharmacology, 2015, 18, pyu050-pyu050.	1.0	13
11	P.2.10 Hippocampal Cx43 hemichannel inactivation protects from glutamatergic stress-related behaviour. European Neuropsychopharmacology, 2019, 29, S661-S662.	0.3	0